MosaiQ by Quotient Wins Prestigious Red Dot Design Award
April 12 2021 - 9:00AM
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics
company (the Company), today announced that the company has been
recognized with a 2021 Red Dot Product Design Award for the full
MosaiQ™ by Quotient system.
MosaiQ is designed to deliver rapid immunohematology,
serological and molecular disease screening, using a single low
volume sample on a high throughput, multimodal multiplexing
automated platform. MosaiQ represents a transformative and
potentially highly disruptive unified testing system for
transfusion diagnostics and beyond.
The Red Dot Award is an international design prize awarded in
annual competitions held since 1955.
“The international jury only awards this sought-after seal of
quality to products that feature an outstanding design. Your
product, MosaiQ™ by Quotient, was able to convince our jurors and
receives an award in the Red Dot Award: Product Design 2021
category. Congratulations on this great achievement,” said
Professor Dr. Peter Zec, Founder and CEO of Red Dot.
“We are honored to receive international recognition in the form
of this prestigious award. This stands as a testament to our
partners’ and our team’s creativity and design efforts throughout
the years. Our system was specifically designed to address the
challenges of today’s resource-constrained diagnostic environments
to help improve clinical decision making,” said Manuel O. Mendez,
Chief Executive Officer of Quotient.
About Quotient Limited
Building on over 30 years of experience in transfusion
diagnostics, Quotient is a commercial-stage diagnostics company
committed to delivering solutions that reshape the way diagnostics
is practiced. MosaiQ, Quotient’s proprietary multiplex microarray
technology, offers the world’s first fully automated, consolidated
testing platform, allowing for multiple tests across different
modalities. MosaiQ is designed to be a game-changing solution,
which Quotient believes will increase efficiencies, improve
clinical practice, deliver significant workflow improvements, and
operational cost savings to laboratories around the world. In
response to the global effort to combat COVID-19, Quotient
developed the MosaiQ COVID-19 Antibody Microarray which is CE
marked and has received the U.S. FDA Emergency Use Authorization.
Quotient's operations are based in Eysins, Switzerland, Edinburgh,
Scotland and Newtown, Pennsylvania.
Contact: Peter Buhler, Chief Financial Officer,
IR@quotientbd.com; +41 22 545 52 26
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Sep 2023 to Sep 2024